Deal Type: Majority Recapitalization
Exit: Sale to strategic buyer
In 2009, we partnered with management to acquire the majority of the Introgen assets out of bankruptcy. Introgen had built out clean room facilities and developed manufacturing expertise for its internal use. We rebranded the company and re-launched as a third party manufacturer of viral vectors for customers who needed scaled quantities for their biopharmaceutical portfolio assets. Vivante GMP Solutions was the result of that strategy. Vivante was acquired in 2010 by Swiss-based LONZA, one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries.